These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7747704)

  • 1. Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndrome. A phase II trial.
    Nemunaitis J; Rosenfeld C; Getty L; Boegel F; Meyer W; Jennings LW; Zeigler Z; Shadduck R
    Am J Clin Oncol; 1995 Jun; 18(3):189-93. PubMed ID: 7747704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma.
    Thompson JA; Bianco JA; Benyunes MC; Neubauer MA; Slattery JT; Fefer A
    Cancer Res; 1994 Jul; 54(13):3436-41. PubMed ID: 8012963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hematologic response to anti-apoptotic cytokine therapy: results of pentoxifylline, ciprofloxacin, and dexamethasone treatment for patients with myelodysplastic syndrome.
    Kim MK; Lee JL; Cho HS; Bae SH; Ryoo HM; Lee KH; Hyun MS
    J Korean Med Sci; 2006 Feb; 21(1):40-5. PubMed ID: 16479063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose escalation of busulfan with pentoxifylline and ciprofloxacin in patients with breast cancer undergoing autologous transplants.
    Bensinger WI; Buckner CD; Lilleby K; Holmberg L; Storb R; Slattery JT
    Oncology; 2004; 67(5-6):368-75. PubMed ID: 15713992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of CYP1A2 and CYP2E1 in the pentoxifylline ciprofloxacin drug interaction.
    Peterson TC; Peterson MR; Wornell PA; Blanchard MG; Gonzalez FJ
    Biochem Pharmacol; 2004 Jul; 68(2):395-402. PubMed ID: 15194011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications.
    Ferrà C; de Sanjosé S; Lastra CF; Martí F; Mariño EL; Sureda A; Brunet S; Gallardo D; Berlanga JJ; García J; Grañena A
    Bone Marrow Transplant; 1997 Dec; 20(12):1075-80. PubMed ID: 9466281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor-alpha levels decrease with anticytokine therapy in patients with myelodysplastic syndromes.
    Reza S; Shetty V; Dar S; Qawi H; Raza A
    J Interferon Cytokine Res; 1998 Oct; 18(10):871-7. PubMed ID: 9809623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation.
    Bianco JA; Appelbaum FR; Nemunaitis J; Almgren J; Andrews F; Kettner P; Shields A; Singer JW
    Blood; 1991 Sep; 78(5):1205-11. PubMed ID: 1878587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of oral pentoxifylline on the cytokine release syndrome during inductive OKT3.
    DeVault GA; Kohan DE; Nelson EW; Holman JM
    Transplantation; 1994 Feb; 57(4):532-40. PubMed ID: 8116037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pentoxifylline on tumor necrosis factor-alpha and interleukin-6 levels in neonatal sepsis.
    Selim K; Hüseyin C; Ibrahim KH; Hasan BU; Kazim U; Hüseyin K
    Med J Malaysia; 2004 Aug; 59(3):391-4. PubMed ID: 15727386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pentoxifylline for the treatment of HIV infection and its complications.
    Dezube BJ; Lederman MM
    J Cardiovasc Pharmacol; 1995; 25 Suppl 2():S139-42. PubMed ID: 8699854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pentoxifylline on cytokine patterns in the therapy of complicated Plasmodium falciparum malaria.
    Wenisch C; Looareesuwan S; Wilairatana P; Parschalk B; Vannapann S; Wanaratana V; Wernsdorfer W; Graninger W
    Am J Trop Med Hyg; 1998 Mar; 58(3):343-7. PubMed ID: 9546416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial.
    Attal M; Huguet F; Rubie H; Charlet JP; Schlaifer D; Huynh A; Laurent G; Pris J
    Blood; 1993 Aug; 82(3):732-6. PubMed ID: 8338943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of pentoxifylline on the cytokines that may play a role in rejection and resistive index in renal transplant recipients.
    Demir E; Paydas S; Balal M; Kurt C; Sertdemir Y; Erken U
    Transplant Proc; 2006 Nov; 38(9):2883-6. PubMed ID: 17112855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone.
    Raza A; Qawi H; Lisak L; Andric T; Dar S; Andrews C; Venugopal P; Gezer S; Gregory S; Loew J; Robin E; Rifkin S; Hsu WT; Huang RW
    Blood; 2000 Mar; 95(5):1580-7. PubMed ID: 10688811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-alpha) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL).
    Sampaio EP; Moraes MO; Nery JA; Santos AR; Matos HC; Sarno EN
    Clin Exp Immunol; 1998 Feb; 111(2):300-8. PubMed ID: 9486396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased apoptosis of bone marrow cells and preserved proliferative capacity of selected progenitors predict for clinical response to anti-inflammatory therapy in myelodysplastic syndromes.
    Novitzky N; Mohamed R; Finlayson J; du Toit C
    Exp Hematol; 2000 Aug; 28(8):941-9. PubMed ID: 10989195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization.
    Mizutani Y; Bonavida B; Nio Y; Yoshida O
    J Urol; 1994 Jun; 151(6):1697-702. PubMed ID: 8189599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The maximal tolerable intravenous dosage of pentoxifylline in AIDS patients does not inhibit lipopolysaccharide-stimulated tumor necrosis factor alpha production.
    Heijligenberg R; Romijn JA; Ackermans M; Endert E; Timmer JG; Sauerwein HP
    AIDS Res Hum Retroviruses; 1998 Mar; 14(4):299-303. PubMed ID: 9519890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of intravenous pentoxifylline in inflammatory response in patients undergoing nephrolithotomy.
    Izadpanah F; Mojtahedzadeh M; Kazem Aghamir SM; Atharikia D; Dashti S; Abbasi A
    J Endourol; 2009 Feb; 23(2):323-8. PubMed ID: 19220089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.